Ruben A. Mesa, MD of Mayo Clinic gives an overview of the upcoming treatment trends for myeloproliferative neoplasms, which include new FDA approved agents, JAK inhibitors, and combination studies. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
Myeloproliferative Neoplasm Trends for 2017
